Mitglied werden

AbbVie Inc. (ABBV)

Healthcare • Drug Manufacturers - General

37
Beobachten
$225,63
Kurs
0,00%
Veränderung
398,77 Mrd. $
Marktkapitalisierung
73,48
KGV

Neumann-Score Aktienanalyse

37
von 100 Punkten
Beobachten
Bewertung??/100
Profitabilität??/100
Wachstum??/100

Score-Details freischalten

Werden Sie Mitglied und erhalten Sie Zugang zu allen Analysen.

Mitglied werden

Über AbbVie Inc.

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to trea ...

CEO
Robert A. Michael
Mitarbeiter
55.000
Land
US